Verena Theiler-Schwetz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Verena Theiler-Schwetz has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Christian Trummer
Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
4 shared publications - Stefan Pilz
Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria
4 shared publications - Barbara Obermayer-Pietsch
Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
2 shared publications - Lisa Schmitt
Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria
2 shared publications A. Fahrleitner-Pammer
Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Styria, Austria
1 shared publicationAlbert Wölfler
Division of Haematology Department of Internal Medicine Medical University of Graz Auenbruggerplatz 15 8036 Graz Austria
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 2 January 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 91
Effects of modified release hydrocortisone on restoration of early morning cortisol, quality of life, and fatigue in adrenal insufficiency (The CHAMPAIN study): a randomised, double-blind, double-dummy, cross-over study comparing Chronocort and Plenadren
- 2 January 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 91
Top Cited PapersOpen AccessEffects of modified release hydrocortisone on restoration of early morning cortisol, quality of life, and fatigue in adrenal insufficiency (The CHAMPAIN study): a randomised, double-blind, double-dummy, cross-over study comparing Chronocort and Plenadren
- Open Access
- 18 October 2024
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 68, e240035
Rebound hypercalcemia after denosumab cessation during follow-up after surgical treatment for parathyroid carcinoma: case report and literature review
SUMMARY Denosumab is a potent antiresorptive medication, commonly used in the treatment of osteoporosis, as well as in a variety of other diseases. Potential adverse rebound effects after its cessation include a loss in bone mineral density and an increased risk of osteoporotic fractures. Hypercalcemia is a less frequently reported rebound phenomenon after denosumab discontinuation, that may pose a diagnostic challenge to physicians as a rare non-parathyroid hormone (PTH) dependent cause of hypercalcemia. In our case, a 47-year-old male presented [...] SUMMARY Denosumab is a potent antiresorptive medication, commonly used in the treatment of osteoporosis, as well as in a variety of other diseases. Potential adverse rebound effects after its cessation include a loss in bone mineral density and an increased risk of osteoporotic fractures. Hypercalcemia is a less frequently reported rebound phenomenon after denosumab discontinuation, that may pose a diagnostic challenge to physicians as a rare non-parathyroid hormone (PTH) dependent cause of hypercalcemia. In our case, a 47-year-old male presented
- 18 October 2024
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 68, e240035
Open AccessRebound hypercalcemia after denosumab cessation during follow-up after surgical treatment for parathyroid carcinoma: case report and literature review
SUMMARY Denosumab is a potent antiresorptive medication, commonly used in the treatment of osteoporosis, as well as in a variety of other diseases. Potential adverse rebound effects after its cessation include a loss in bone mineral density and an increased risk of osteoporotic fractures. Hypercalcemia is a less frequently reported rebound phenomenon after denosumab discontinuation, that may pose a diagnostic challenge to physicians as a rare non-parathyroid hormone (PTH) dependent cause of hypercalcemia. In our case, a 47-year-old male presented [...] SUMMARY Denosumab is a potent antiresorptive medication, commonly used in the treatment of osteoporosis, as well as in a variety of other diseases. Potential adverse rebound effects after its cessation include a loss in bone mineral density and an increased risk of osteoporotic fractures. Hypercalcemia is a less frequently reported rebound phenomenon after denosumab discontinuation, that may pose a diagnostic challenge to physicians as a rare non-parathyroid hormone (PTH) dependent cause of hypercalcemia. In our case, a 47-year-old male presented
- Open Access
- 22 April 2024
- Published by Springer Nature in Endocrine
- Vol. 85 (2) , 926-936
No requirement of perioperative glucocorticoid replacement in patients with endogenous Cushing’s syndrome – a pilot study
Purpose: Surgical therapy represents the first-line treatment for endogenous Cushing’s syndrome (CS). While postoperative glucocorticoid replacement is mandatory after surgical remission, the role of perioperative glucocorticoid therapy is unclear. Methods: We recruited patients with central or adrenal CS in whom curative surgery was planned and patients who underwent pituitary surgery for other reasons than CS as a control group. Patients did not receive any perioperative glucocorticoids until the morning of the first postoperative day. We performed blood samplings in the morning of surgery, immediately after surgery, in the evening of the day of surgery, and in the morning of the first and third postoperative day before any morning glucocorticoid intake. We continued clinical and biochemical monitoring during the following outpatient care. Results: We recruited 12 patients with CS (seven with central CS, five with adrenal CS) and six patients without CS. In patients with CS, serum cortisol concentrations 138 nmol/L) after 129 ± 97 days and glucocorticoids were discontinued after 402 ± 243 days. Patients without CS did not require glucocorticoid replacement at any time. Conclusion: Perioperative glucocorticoid replacement may be unnecessary in patients with central or adrenal CS undergoing curative surgery as first-line treatment.
- 22 April 2024
- Published by Springer Nature in Endocrine
- Vol. 85 (2) , 926-936
Open AccessNo requirement of perioperative glucocorticoid replacement in patients with endogenous Cushing’s syndrome – a pilot study
Purpose: Surgical therapy represents the first-line treatment for endogenous Cushing’s syndrome (CS). While postoperative glucocorticoid replacement is mandatory after surgical remission, the role of perioperative glucocorticoid therapy is unclear. Methods: We recruited patients with central or adrenal CS in whom curative surgery was planned and patients who underwent pituitary surgery for other reasons than CS as a control group. Patients did not receive any perioperative glucocorticoids until the morning of the first postoperative day. We performed blood samplings in the morning of surgery, immediately after surgery, in the evening of the day of surgery, and in the morning of the first and third postoperative day before any morning glucocorticoid intake. We continued clinical and biochemical monitoring during the following outpatient care. Results: We recruited 12 patients with CS (seven with central CS, five with adrenal CS) and six patients without CS. In patients with CS, serum cortisol concentrations 138 nmol/L) after 129 ± 97 days and glucocorticoids were discontinued after 402 ± 243 days. Patients without CS did not require glucocorticoid replacement at any time. Conclusion: Perioperative glucocorticoid replacement may be unnecessary in patients with central or adrenal CS undergoing curative surgery as first-line treatment.
- Open Access
- 11 November 2021
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 65 (6) , 846-851
Acute suppurative thyroiditis due to Streptococcus anginosus leading to sepsis and acute respiratory distress syndrome: a case report
SUMMARY Acute suppurative thyroiditis (AST) is a rare but potentially life-threatening thyroid disease with a high mortality if left untreated. Thus, differentiation from other thyroid disorders is highly important in clinical practice. A 22-year-old male patient was admitted to a tertiary care hospital with cervical pain, palpitations, thyrotoxicosis, and an inhomogeneously enlarged right thyroid lobe. In view of the clinical findings, subacute thyroiditis (SAT) was suspected and treatment with glucocorticoids was started. After initial amelioration, the patient developed cervical erythema, [...] SUMMARY Acute suppurative thyroiditis (AST) is a rare but potentially life-threatening thyroid disease with a high mortality if left untreated. Thus, differentiation from other thyroid disorders is highly important in clinical practice. A 22-year-old male patient was admitted to a tertiary care hospital with cervical pain, palpitations, thyrotoxicosis, and an inhomogeneously enlarged right thyroid lobe. In view of the clinical findings, subacute thyroiditis (SAT) was suspected and treatment with glucocorticoids was started. After initial amelioration, the patient developed cervical erythema,
- 11 November 2021
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 65 (6) , 846-851
Open AccessAcute suppurative thyroiditis due to Streptococcus anginosus leading to sepsis and acute respiratory distress syndrome: a case report
SUMMARY Acute suppurative thyroiditis (AST) is a rare but potentially life-threatening thyroid disease with a high mortality if left untreated. Thus, differentiation from other thyroid disorders is highly important in clinical practice. A 22-year-old male patient was admitted to a tertiary care hospital with cervical pain, palpitations, thyrotoxicosis, and an inhomogeneously enlarged right thyroid lobe. In view of the clinical findings, subacute thyroiditis (SAT) was suspected and treatment with glucocorticoids was started. After initial amelioration, the patient developed cervical erythema, [...] SUMMARY Acute suppurative thyroiditis (AST) is a rare but potentially life-threatening thyroid disease with a high mortality if left untreated. Thus, differentiation from other thyroid disorders is highly important in clinical practice. A 22-year-old male patient was admitted to a tertiary care hospital with cervical pain, palpitations, thyrotoxicosis, and an inhomogeneously enlarged right thyroid lobe. In view of the clinical findings, subacute thyroiditis (SAT) was suspected and treatment with glucocorticoids was started. After initial amelioration, the patient developed cervical erythema,
- Open Access
- 1 January 2021
- Published by Media Sphere Publishing Group in Laboratory Service
- Vol. 10 (2) , 55
Vitamin D testing and treatment: a narrative review of current evidence
Определение витамина D и лечение его дефицита — до сих пор предмет научных споров и дискуссий, поэтому было сложно охватить растущее количество публикаций с различными и частично противоположными мнениями и рекомендациями. В этом обзоре представлена обновленная информация о руководствах по витамину D, о его роли для поддержания здоровья человека и основанных на этих данных возможных действиях систем здравоохранения. Витамин D имеет решающее значение для костного и минерального обмена, и установлено, что недостаток витамина D может вызвать рахит и остеомаляцию. Хотя многие руководства рекомендуют в качестве целевой концентрации 25-гидроксивитамина D (25(OH)D) в сыворотке крови ≥50 нмоль/л (20 нг/мл), научное сообщество пришло к согласию только в том, что сывороточная концентрация 25(OH)D ниже 25—30 нмоль/л (10—12 нг/мл) требует профилактики и лечения. Принятие этого порога концентрации 25(OH)D в сыворотке показало, что в мире существует высокая распространенность дефицита витамина D, и это может потребовать от систем здравоохранения таких действий, как обогащение пищи витамином D. С другой стороны, причиной для беспокойства является растущий объем тестирования и приема добавок витамина D, что увеличивает затраты и может причинить вред. В научной дискуссии о витамине D мы должны иметь в виду, что испытания питательных веществ отличаются от испытаний лекарственных средств и что, кроме описания противоположных точек зрения в отношении показаний к лечению витамином D, нам еще предстоит охарактеризовать роль витамина D для поддержания здоровья человека.
- 1 January 2021
- Published by Media Sphere Publishing Group in Laboratory Service
- Vol. 10 (2) , 55
Open AccessVitamin D testing and treatment: a narrative review of current evidence
Определение витамина D и лечение его дефицита — до сих пор предмет научных споров и дискуссий, поэтому было сложно охватить растущее количество публикаций с различными и частично противоположными мнениями и рекомендациями. В этом обзоре представлена обновленная информация о руководствах по витамину D, о его роли для поддержания здоровья человека и основанных на этих данных возможных действиях систем здравоохранения. Витамин D имеет решающее значение для костного и минерального обмена, и установлено, что недостаток витамина D может вызвать рахит и остеомаляцию. Хотя многие руководства рекомендуют в качестве целевой концентрации 25-гидроксивитамина D (25(OH)D) в сыворотке крови ≥50 нмоль/л (20 нг/мл), научное сообщество пришло к согласию только в том, что сывороточная концентрация 25(OH)D ниже 25—30 нмоль/л (10—12 нг/мл) требует профилактики и лечения. Принятие этого порога концентрации 25(OH)D в сыворотке показало, что в мире существует высокая распространенность дефицита витамина D, и это может потребовать от систем здравоохранения таких действий, как обогащение пищи витамином D. С другой стороны, причиной для беспокойства является растущий объем тестирования и приема добавок витамина D, что увеличивает затраты и может причинить вред. В научной дискуссии о витамине D мы должны иметь в виду, что испытания питательных веществ отличаются от испытаний лекарственных средств и что, кроме описания противоположных точек зрения в отношении показаний к лечению витамином D, нам еще предстоит охарактеризовать роль витамина D для поддержания здоровья человека.
- Open Access
- 28 November 2017
- Published by Wiley in Clinical Case Reports
- Vol. 6 (1) , 78-81
Visceral leishmaniasis in a patient with diabetes mellitus type 2 and discrete bicytopenia
Key Clinical Message: An Austrian patient with diabetes mellitus type 2 developed visceral leishmaniasis after trips to Spain and Crete, presenting with slight bicytopenia, later developing severe pancytopenia. Travel history taking is important due to an extended incubation period. Coexistence of diabetes mellitus can impair T lymphocyte function and cause higher relapse rates.
- 28 November 2017
- Published by Wiley in Clinical Case Reports
- Vol. 6 (1) , 78-81
Open AccessVisceral leishmaniasis in a patient with diabetes mellitus type 2 and discrete bicytopenia
Key Clinical Message: An Austrian patient with diabetes mellitus type 2 developed visceral leishmaniasis after trips to Spain and Crete, presenting with slight bicytopenia, later developing severe pancytopenia. Travel history taking is important due to an extended incubation period. Coexistence of diabetes mellitus can impair T lymphocyte function and cause higher relapse rates.
- Open Access
- 25 August 2017
- Published by Springer Nature in Osteoporosis International
- Vol. 28 (12) , 3347-3354
Effect of vitamin D3 on bone turnover markers in critical illness: post hoc analysis from the VITdAL-ICU study
Summary In this post hoc analysis of the VITdAL-ICU study, an RCT in critically ill adults with 25-hydroxyvitamin D levels ≤20 ng/ml, vitamin D3 did not have a significant effect on β-Crosslaps and osteocalcin. Introduction Observational studies have shown accelerated bone loss in ICU survivors. A reversible contributor is vitamin D deficiency. In a post hoc analysis of the VITdAL-ICU study, we evaluated the effect of high-dose vitamin D3 on the bone turnover markers (BTM) β-Crosslaps (CTX) and osteocalcin (OC). Methods The VITdAL-ICU study was a randomized, double-blind, placebo-controlled trial in critically ill adults with 25-hydroxyvitamin D levels ≤20 ng/ml who received placebo or high-dose vitamin D3 (a loading dose of 540,000 IU and starting 1 month after the loading dose five monthly maintenance doses of 90,000 IU). In this analysis on 289 survivors (209 telephone, 80 personal follow-up visits), BTM were analyzed on days 0, 3, 7, 28, and 180; self-reported falls and fractures were assessed. Bone mineral density (BMD) was measured after 6 months. Results At baseline, CTX was elevated; OC was low in both groups—after 6 months, both had returned to normal. There were no differences between groups concerning BTM, BMD, falls, or fractures. In linear mixed effects models, CTX and OC showed a significant change over time (p < 0.001, respectively), but there was no difference between the vitamin D and placebo group (p = 0.688 and p = 0.972, respectively). Conclusions Vitamin D supplementation did not have a significant effect on BTM. Further studies should assess the effectiveness of vitamin D on musculoskeletal outcomes in ICU survivors.
- 25 August 2017
- Published by Springer Nature in Osteoporosis International
- Vol. 28 (12) , 3347-3354
Open AccessEffect of vitamin D3 on bone turnover markers in critical illness: post hoc analysis from the VITdAL-ICU study
Summary In this post hoc analysis of the VITdAL-ICU study, an RCT in critically ill adults with 25-hydroxyvitamin D levels ≤20 ng/ml, vitamin D3 did not have a significant effect on β-Crosslaps and osteocalcin. Introduction Observational studies have shown accelerated bone loss in ICU survivors. A reversible contributor is vitamin D deficiency. In a post hoc analysis of the VITdAL-ICU study, we evaluated the effect of high-dose vitamin D3 on the bone turnover markers (BTM) β-Crosslaps (CTX) and osteocalcin (OC). Methods The VITdAL-ICU study was a randomized, double-blind, placebo-controlled trial in critically ill adults with 25-hydroxyvitamin D levels ≤20 ng/ml who received placebo or high-dose vitamin D3 (a loading dose of 540,000 IU and starting 1 month after the loading dose five monthly maintenance doses of 90,000 IU). In this analysis on 289 survivors (209 telephone, 80 personal follow-up visits), BTM were analyzed on days 0, 3, 7, 28, and 180; self-reported falls and fractures were assessed. Bone mineral density (BMD) was measured after 6 months. Results At baseline, CTX was elevated; OC was low in both groups—after 6 months, both had returned to normal. There were no differences between groups concerning BTM, BMD, falls, or fractures. In linear mixed effects models, CTX and OC showed a significant change over time (p < 0.001, respectively), but there was no difference between the vitamin D and placebo group (p = 0.688 and p = 0.972, respectively). Conclusions Vitamin D supplementation did not have a significant effect on BTM. Further studies should assess the effectiveness of vitamin D on musculoskeletal outcomes in ICU survivors.
- 6 December 2012
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 23 (2) , e15-e16
Hypertriglyceridemic waist is associated with impaired glucose tolerance in polycystic ovary syndrome
- 6 December 2012
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 23 (2) , e15-e16
Hypertriglyceridemic waist is associated with impaired glucose tolerance in polycystic ovary syndrome